Lam Research's Q1 2026 Earnings Announcement Tests AI Narrative Amid High Valuation and Geopolitical Risks

What happened

Lam Research has reported its financial results for the quarter ended March 29, 2026, a key checkpoint per the DeepValue report's guidance of $5.70B ± $0.30B revenue. The report highlights that at a P/E of 43.3, the stock prices in a sustained AI-driven upcycle, but recent performance skews foundry-led with a 60% mix versus 34% memory, undermining the pure AI-memory narrative. Critical risks include China revenue exposure at 39% for the six months ended December 2025 and conversion delays, with $226M in Japan shipments pending acceptance as of that date. Investors must scrutinize whether revenue met the guided range and if China share remained stable, as deviations could signal export-license issues or timing frictions. This earnings release serves as a reality check for the company's ability to convert demand into recognized revenue while justifying its premium valuation amid crowded market sentiment.

Implication

The earnings report reinforces the need for caution, with the DeepValue report's WAIT rating suggesting holding off until clearer evidence of sustained performance or a lower entry price near $180. If revenue meets guidance, it supports the base case but doesn't alleviate overvaluation concerns at 43.3x P/E, where even minor setbacks could compress the multiple. A miss would highlight conversion risks, such as shipment delays, and challenge the AI-driven demand assumptions embedded in the stock price. Stability in China revenue share around 33% or above is crucial; a drop could indicate licensing headwinds that impair long-term growth and trigger the bear case. Overall, this update underscores that the stock lacks a margin of safety, with geopolitical and operational headwinds demanding a disciplined wait-and-see approach rather than buying into the crowded narrative.

Thesis delta

The thesis remains unchanged unless the reported revenue significantly deviates from the $5.70B ± $0.30B guidance or China revenue share shifts materially from recent levels. If results align, it confirms the base scenario but doesn't justify moving from a WAIT rating, given the elevated valuation and ongoing risks like export controls. A negative surprise would strengthen the bear case, emphasizing conversion fragility and China dependency, potentially lowering the attractive entry point.